BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22740943)

  • 1. Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.
    Takakura A; Kurita A; Asahara T; Yokoba M; Yamamoto M; Ryuge S; Igawa S; Yasuzawa Y; Sasaki J; Kobayashi H; Masuda N
    Oncol Lett; 2012 Mar; 3(3):520-524. PubMed ID: 22740943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
    Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
    Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept.
    Martha L; Nakata A; Furuya S; Liu W; Zhang X; Mizoi K; Ogihara T
    Biochem Biophys Res Commun; 2023 Jul; 665():19-25. PubMed ID: 37148742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
    Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
    PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.
    Hirose K; Kozu C; Yamashita K; Maruo E; Kitamura M; Hasegawa J; Omoda K; Murakami T; Maeda Y
    Oncol Lett; 2012 Mar; 3(3):694-698. PubMed ID: 22740978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
    Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
    Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
    Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
    Mick R; Gupta E; Vokes EE; Ratain MJ
    J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of irinotecan.
    Kuhn JG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.
    Kodawara T; Higashi T; Negoro Y; Kamitani Y; Igarashi T; Watanabe K; Tsukamoto H; Yano R; Masada M; Iwasaki H; Nakamura T
    Basic Clin Pharmacol Toxicol; 2016 May; 118(5):333-7. PubMed ID: 26518357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
    Kurita A; Kaneda N
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.
    Ahmad S; Hughes MA; Lane KT; Redinbo MR; Yeh LA; Scott JE
    Curr Chem Genomics; 2011; 5():13-20. PubMed ID: 21643506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
    Fujita D; Saito Y; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.
    Guan HY; Li PF; Wang XM; Yue JJ; He Y; Luo XM; Su MF; Liao SG; Shi Y
    Front Pharmacol; 2017; 8():769. PubMed ID: 29163158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.